Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    sgn-33
Show Display Options
Rank Status Study
1 Completed A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
Condition: Acute Myeloid Leukemia
Interventions: Drug: Lintuzumab (SGN-33);   Drug: Low dose cytarabine;   Drug: Placebo
2 Completed A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Disorders;   Chronic Myelomonocytic Leukemia
Intervention: Drug: lintuzumab
3 Completed A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndrome (MDS)
Interventions: Drug: lintuzumab;   Drug: lenalidomide
4 Terminated
Has Results
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Biological: lintuzumab;   Drug: 5-azacytidine
5 Recruiting A Safety Study of SGN-CD33A in AML Patients
Conditions: Acute Myelogenous Leukemia;   Acute Myeloid Leukemia;   Acute Promyelocytic Leukemia;   APL
Interventions: Drug: HMA;   Drug: SGN-CD33A
6 Recruiting Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Recurrent Adult Hodgkin Lymphoma
Interventions: Biological: ipilimumab;   Drug: brentuximab vedotin;   Other: laboratory biomarker analysis
7 Not yet recruiting Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
Condition: Hodgkin Lymphoma
Intervention: Drug: brentuximab vedotin

Indicates status has not been verified in more than two years